Future studies should elucidate whether the preferential loss of SPARCL1 in various malignomas is due to its function as a vascular-derived tumor suppressor favouring vessel homeostasis, as reported for colorectal carcinoma. This evidence concerns the gene SPARCL1 and neoplasm.